Top

Published in:

01-09-2011 | Review

Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond

Authors: Santosh K. Sanganalmath, Ahmed Abdel-Latif, Roberto Bolli, Yu-Ting Xuan, Buddhadeb Dawn

Published in: Basic Research in Cardiology | Issue 5/2011

Abstract

Hematopoietic cytokines, traditionally known to influence cellular proliferation, differentiation, maturation, and lineage commitment in the bone marrow, include granulocyte colony-stimulating factor (G-CSF), granulocyte–macrophage colony-stimulating factor, stem cell factor, Flt-3 ligand, and erythropoietin among others. Emerging evidence suggests that these cytokines also exert multifarious biological effects on diverse nonhematopoietic organs and tissues. Although the precise mechanisms remain unclear, numerous studies in animal models of myocardial infarction (MI) and heart failure indicate that hematopoietic cytokines confer potent cardiovascular benefits, possibly through mobilization and subsequent homing of bone marrow-derived cells into the infarcted heart with consequent induction of myocardial repair involving multifarious mechanisms. In addition, these cytokines are also known to exert direct cytoprotective effects. However, results from small-scale clinical trials of G-CSF therapy as a single agent after acute MI have been discordant and largely disappointing. It is likely that cardiac repair following cytokine therapy depends on a number of known and unknown variables, and further experimental and clinical studies are certainly warranted to accurately determine the true therapeutic potential of such therapy. In this review, we discuss the biological features of several key hematopoietic cytokines and present the basic and clinical evidence pertaining to cardiac repair with hematopoietic cytokine therapy.

Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B (2007) Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167:989–997. doi:10.1001/archinte.167.10.989 PubMedCrossRef

Abdel-Latif A, Bolli R, Zuba-Surma EK, Tleyjeh IM, Hornung CA, Dawn B (2008) Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J 156:216–226 e219. doi:10.1016/j.ahj.2008.03.024

Abraham SN, Malaviya R (1997) Mast cells in infection and immunity. Infect Immun 65:3501–3508PubMed

Achilli F, Malafronte C, Lenatti L, Gentile F, Dadone V, Gibelli G, Maggiolini S, Squadroni L, Di Leo C, Burba I, Pesce M, Mircoli L, Capogrossi MC, Di Lelio A, Camisasca P, Morabito A, Colombo G, Pompilio G (2010) Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the single-blind, randomized, placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) Trial. Eur J Heart Fail 12:1111–1121. doi:10.1093/eurjhf/hfq150 PubMedCrossRef

Adachi Y, Imagawa J, Suzuki Y, Yogo K, Fukazawa M, Kuromaru O, Saito Y (2004) G-CSF treatment increases side population cell infiltration after myocardial infarction in mice. J Mol Cell Cardiol 36:707–710. doi:10.1016/j.yjmcc.2004.03.005 PubMedCrossRef

Angeli FS, Amabile N, Shapiro M, Mirsky R, Bartlett L, Zhang Y, Virmani R, Chatterjee K, Boyle A, Grossman W, Yeghiazarians Y (2010) Cytokine combination therapy with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction. Cardiovasc Drugs Ther. doi:10.1007/s10557-010-6263-7

Angeli FS, Smith C, Amabile N, Shapiro M, Bartlett L, Virmani R, Chatterjee K, Boyle A, Grossman W, Yeghiazarians Y (2010) Granulocyte colony stimulating factor in myocardial infarction with low ejection fraction. Cytokine 51:278–285. doi:10.1016/j.cyto.2010.06.003 PubMedCrossRef

Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS (2003) Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362:697–703PubMedCrossRef

Belonje AM, Voors AA, van Gilst WH, Anker SD, Slart RH, Tio RA, Zijlstra F, van Veldhuisen DJ (2008) Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 155:817–822. doi:10.1016/j.ahj.2007.12.036 PubMedCrossRef

10.

Beohar N, Flaherty JD, Davidson CJ, Vidovich M, Singhal S, Rapp JA, Erdogan A, Lee DC, Rammohan C, Brodsky A, Wu E, Pieper K, Virmani R, Bonow RO, Mehta J (2007) Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing. Catheter Cardiovasc Interv 69:257–266PubMedCrossRef

11.

Bikfalvi A, Han ZC (1994) Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia 8:523–529PubMed

12.

Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE (2009) Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 104:1035–1040. doi:10.1016/j.amjcard.2009.05.050 PubMedCrossRef

13.

Bodine DM, Seidel NE, Gale MS, Nienhuis AW, Orlic D (1994) Efficient retrovirus transduction of mouse pluripotent hematopoietic stem cells mobilized into the peripheral blood by treatment with granulocyte colony-stimulating factor and stem cell factor. Blood 84:1482–1491PubMed

14.

Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R (2008) The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 120:172–185. doi:10.1016/j.pharmthera.2008.08.002 PubMedCrossRef

15.

Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T (2000) Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood 95:270–276PubMed

16.

Broudy VC (1997) Stem cell factor and hematopoiesis. Blood 90:1345–1364PubMed

17.

Brunner S, Huber BC, Fischer R, Groebner M, Hacker M, David R, Zaruba MM, Vallaster M, Rischpler C, Wilke A, Gerbitz A, Franz WM (2008) G-CSF treatment after myocardial infarction: impact on bone marrow-derived vs cardiac progenitor cells. Exp Hematol 36:695–702. doi:10.1016/j.exphem.2008.01.011 PubMedCrossRef

18.

Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q (2006) Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 72:51–59PubMedCrossRef

19.

Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O, Bosia A, Marchisio PC, Mantovani A (1991) In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 87:986–995PubMedCrossRef

20.

Cai Z, Semenza GL (2004) Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 109:2050–2053PubMedCrossRef

21.

Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100:4802–4806. doi:10.1073/pnas.06304441000630444100 PubMedCrossRef

22.

Capoccia BJ, Shepherd RM, Link DC (2006) G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism. Blood 108:2438–2445PubMedCrossRef

23.

Cheng Z, Ou L, Liu Y, Liu X, Li F, Sun B, Che Y, Kong D, Yu Y, Steinhoff G (2008) Granulocyte colony-stimulating factor exacerbates cardiac fibrosis after myocardial infarction in a rat model of permanent occlusion. Cardiovasc Res 80:425–434. doi:10.1093/cvr/cvn202 PubMedCrossRef

24.

Dawn B, Abdel-Latif A, Sanganalmath SK, Flaherty MP, Zuba-Surma EK (2009) Cardiac repair with adult bone marrow-derived cells: the clinical evidence. Antioxid Redox Signal 11:1865–1882. doi:10.1089/ARS.2009.2462 PubMedCrossRef

25.

Dawn B, Guo Y, Rezazadeh A, Huang Y, Stein AB, Hunt G, Tiwari S, Varma J, Gu Y, Prabhu SD, Kajstura J, Anversa P, Ildstad ST, Bolli R (2006) Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ Res 98:1098–1105PubMedCrossRef

26.

de Koning JP, Soede-Bobok AA, Ward AC, Schelen AM, Antonissen C, van Leeuwen D, Lowenberg B, Touw IP (2000) STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene 19:3290–3298. doi:10.1038/sj.onc.1203627 PubMedCrossRef

27.

Dedhar S, Gaboury L, Galloway P, Eaves C (1988) Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin. Proc Natl Acad Sci USA 85:9253–9257PubMedCrossRef

28.

Deindl E, Schaper W (2005) The art of arteriogenesis. Cell Biochem Biophys 43:1–15. doi:10.1385/CBB:43:1:001 PubMedCrossRef

29.

Deindl E, Zaruba MM, Brunner S, Huber B, Mehl U, Assmann G, Hoefer IE, Mueller-Hoecker J, Franz WM (2006) G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 20:956–958PubMedCrossRef

30.

Demetri GD, Griffin JD (1991) Granulocyte colony-stimulating factor and its receptor. Blood 78:2791–2808PubMed

31.

Deten A, Volz HC, Clamors S, Leiblein S, Briest W, Marx G, Zimmer HG (2005) Hematopoietic stem cells do not repair the infarcted mouse heart. Cardiovasc Res 65:52–63PubMedCrossRef

32.

Devereux S, Bull HA, Campos-Costa D, Saib R, Linch DC (1989) Granulocyte macrophage colony stimulating factor induced changes in cellular adhesion molecule expression and adhesion to endothelium: in vitro and in vivo studies in man. Br J Haematol 71:323–330PubMedCrossRef

33.

Dewald O, Ren G, Duerr GD, Zoerlein M, Klemm C, Gersch C, Tincey S, Michael LH, Entman ML, Frangogiannis NG (2004) Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol 164:665–677. doi:10.1016/S0002-9440(10)63154-9 PubMedCrossRef

34.

Duarte RF, Frank DA (2000) SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways. Blood 96:3422–3430PubMed

35.

Ellis SG, Penn MS, Bolwell B, Garcia M, Chacko M, Wang T, Brezina KJ, McConnell G, Topol EJ (2006) Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. Am Heart J 152:1051 e1059–1014

36.

Engelmann MG, Theiss HD, Hennig-Theiss C, Huber A, Wintersperger BJ, Werle-Ruedinger AE, Schoenberg SO, Steinbeck G, Franz WM (2006) Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (granulocyte colony-stimulating factor ST-segment elevation myocardial infarction) trial. J Am Coll Cardiol 48:1712–1721PubMedCrossRef

37.

Engelmann MG, Theiss HD, Theiss C, Henschel V, Huber A, Wintersperger BJ, Schoenberg SO, Steinbeck G, Franz WM (2010) G-CSF in patients suffering from late revascularised ST elevation myocardial infarction: final 1-year-results of the G-CSF-STEMI Trial. Int J Cardiol 144:399–404. doi:10.1016/j.ijcard.2009.04.047 PubMedCrossRef

38.

Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C, Campanelli R, Bertoletti A, De Ferrari GM, Klersy C, Angoli L, Bramucci E, Marinoni B, Ferlini M, Moretti E, Raisaro A, Repetto A, Schwartz PJ, Tavazzi L (2009) High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study. Int J Cardiol. doi:10.1016/j.ijcard.2009.10.028

39.

Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228:1–14

40.

Fleming WH, Alpern EJ, Uchida N, Ikuta K, Weissman IL (1993) Steel factor influences the distribution and activity of murine hematopoietic stem cells in vivo. Proc Natl Acad Sci USA 90:3760–3764PubMedCrossRef

41.

Frangogiannis NG, Perrard JL, Mendoza LH, Burns AR, Lindsey ML, Ballantyne CM, Michael LH, Smith CW, Entman ML (1998) Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation 98:687–698PubMed

42.

Friedrich EB, Werner C, Walenta K, Bohm M, Scheller B (2009) Role of extracellular signal-regulated kinase for endothelial progenitor cell dysfunction in coronary artery disease. Basic Res Cardiol 104:613–620. doi:10.1007/s00395-009-0022-6 PubMedCrossRef

43.

Fujita J, Mori M, Kawada H, Ieda Y, Tsuma M, Matsuzaki Y, Kawaguchi H, Yagi T, Yuasa S, Endo J, Hotta T, Ogawa S, Okano H, Yozu R, Ando K, Fukuda K (2007) Administration of granulocyte colony-stimulating factor after myocardial infarction enhances the recruitment of hematopoietic stem cell-derived myofibroblasts and contributes to cardiac repair. Stem Cells 25:2750–2759PubMedCrossRef

44.

Fukuhara S, Tomita S, Nakatani T, Ohtsu Y, Ishida M, Yutani C, Kitamura S (2004) G-CSF promotes bone marrow cells to migrate into infarcted mice heart, and differentiate into cardiomyocytes. Cell Transplant 13:741–748PubMedCrossRef

45.

Fukunaga R, Ishizaka-Ikeda E, Pan CX, Seto Y, Nagata S (1991) Functional domains of the granulocyte colony-stimulating factor receptor. EMBO J 10:2855–2865PubMed

46.

Gamble JR, Elliott MJ, Jaipargas E, Lopez AF, Vadas MA (1989) Regulation of human monocyte adherence by granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA 86:7169–7173PubMedCrossRef

47.

Ghaboura N, Tamareille S, Ducluzeau PH, Grimaud L, Loufrani L, Croue A, Tourmen Y, Henrion D, Furber A, Prunier F (2011) Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3beta signaling. Basic Res Cardiol 106:147–162. doi:10.1007/s00395-010-0130-3 PubMedCrossRef

48.

Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA (1992) Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 124:424–427PubMedCrossRef

49.

Gorgen I, Hartung T, Leist M, Niehorster M, Tiegs G, Uhlig S, Weitzel F, Wendel A (1992) Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J Immunol 149:918–924PubMed

50.

Hamamoto M, Tomita S, Nakatani T, Yutani C, Yamashiro S, Sueda T, Yagihara T, Kitamura S (2004) Granulocyte-colony stimulating factor directly enhances proliferation of human troponin I-positive cells derived from idiopathic dilated cardiomyopathy through specific receptors. J Heart Lung Transplant 23:1430–1437. doi:10.1016/j.healun.2003.09.031 PubMedCrossRef

51.

Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, Ohtsuka M, Matsuura K, Sano M, Nishi J, Iwanaga K, Akazawa H, Kunieda T, Zhu W, Hasegawa H, Kunisada K, Nagai T, Nakaya H, Yamauchi-Takihara K, Komuro I (2005) G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 11:305–311PubMedCrossRef

52.

Hartung T (1998) Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr Opin Hematol 5:221–225PubMedCrossRef

53.

Hartung T, Docke WD, Gantner F, Krieger G, Sauer A, Stevens P, Volk HD, Wendel A (1995) Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85:2482–2489PubMed

54.

Hasegawa H, Takano H, Iwanaga K, Ohtsuka M, Qin Y, Niitsuma Y, Ueda K, Toyoda T, Tadokoro H, Komuro I (2006) Cardioprotective effects of granulocyte colony-stimulating factor in swine with chronic myocardial ischemia. J Am Coll Cardiol 47:842–849PubMedCrossRef

55.

Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102:1340–1346PubMedCrossRef

56.

Hess DA, Levac KD, Karanu FN, Rosu-Myles M, White MJ, Gallacher L, Murdoch B, Keeney M, Ottowski P, Foley R, Chin-Yee I, Bhatia M (2002) Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor. Blood 100:869–878PubMedCrossRef

57.

Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118:1915–1919. doi:10.1161/CIRCULATIONAHA.108.805242 PubMedCrossRef

58.

Hill JM, Bartunek J (2006) The end of granulocyte colony-stimulating factor in acute myocardial infarction? Reaping the benefits beyond cytokine mobilization. Circulation 113:1926–1928PubMedCrossRef

59.

Hill JM, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO 3rd (2005) Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 46:1643–1648. doi:10.1016/j.jacc.2005.01.067 PubMedCrossRef

60.

Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M, Tsukamoto O, Okada K, Koyama H, Komamura K, Takashima S, Shinozaki Y, Mori H, Shiraga M, Kitakaze M, Hori M (2006) Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 48:176–184PubMedCrossRef

61.

Hockel M, Jung W, Vaupel P, Rabes H, Khaledpour C, Wissler JH (1988) Purified monocyte-derived angiogenic substance (angiotropin) induces controlled angiogenesis associated with regulated tissue proliferation in rabbit skin. J Clin Invest 82:1075–1090. doi:10.1172/JCI113664 PubMedCrossRef

62.

Honold J, Lehmann R, Heeschen C, Walter DH, Assmus B, Sasaki K, Martin H, Haendeler J, Zeiher AM, Dimmeler S (2006) Effects of granulocyte colony simulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arterioscler Thromb Vasc Biol 26:2238–2243. doi:10.1161/01.ATV.0000240248.55172.dd PubMedCrossRef

63.

Hossmann KA, Buschmann IR (2005) Granulocyte-macrophage colony-stimulating factor as an arteriogenic factor in the treatment of ischaemic stroke. Expert Opin Biol Ther 5:1547–1556. doi:10.1517/14712598.5.12.1547 PubMedCrossRef

64.

Hou XW, Jiang Y, Wang LF, Xu HY, Lin HM, He XY, He JJ, Zhang S (2009) Protective role of granulocyte colony-stimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. Toxicol Lett 187:40–44. doi:10.1016/j.toxlet.2009.01.025 PubMedCrossRef

65.

Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC (2006) Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 20:85–91PubMedCrossRef

66.

Hristov M, Weber C (2006) The therapeutic potential of progenitor cells in ischemic heart disease—past, present and future. Basic Res Cardiol 101:1–7. doi:10.1007/s00395-005-0573-0 PubMedCrossRef

67.

Huttmann A, Duhrsen U, Stypmann J, Noppeney R, Nuckel H, Neumann T, Gutersohn A, Nikol S, Erbel R (2006) Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure—feasibility, safety and effects on exercise tolerance and cardiac function. Basic Res Cardiol 101:78–86PubMedCrossRef

68.

Ieishi K, Nomura M, Kawano T, Fujimoto S, Ikefuji H, Noda Y, Nishikado A, Ito S (2007) The effect of G-CSF in a myocardial ischemia reperfusion model rat. J Med Invest 54:177–183PubMedCrossRef

69.

Iemura A, Tsai M, Ando A, Wershil BK, Galli SJ (1994) The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 144:321–328PubMed

70.

Ince H, Petzsch M, Kleine HD, Eckard H, Rehders T, Burska D, Kische S, Freund M, Nienaber CA (2005) Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation 112:I73–I80PubMedCrossRef

71.

Ince H, Petzsch M, Kleine HD, Schmidt H, Rehders T, Korber T, Schumichen C, Freund M, Nienaber CA (2005) Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 112:3097–3106PubMedCrossRef

72.

Ince H, Valgimigli M, Petzsch M, de Lezo JS, Kuethe F, Dunkelmann S, Biondi-Zoccai G, Nienaber CA (2008) Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis. Heart 94:610–616PubMedCrossRef

73.

Iwanaga K, Takano H, Ohtsuka M, Hasegawa H, Zou Y, Qin Y, Odaka K, Hiroshima K, Tadokoro H, Komuro I (2004) Effects of G-CSF on cardiac remodeling after acute myocardial infarction in swine. Biochem Biophys Res Commun 325:1353–1359PubMedCrossRef

74.

Jelkmann W, Wagner K (2004) Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 83:673–686PubMedCrossRef

75.

Kanellakis P, Slater NJ, Du XJ, Bobik A, Curtis DJ (2006) Granulocyte colony-stimulating factor and stem cell factor improve endogenous repair after myocardial infarction. Cardiovasc Res 70:117–125PubMedCrossRef

76.

Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo Lee D, Sohn DW, Han KS, Oh BH, Lee MM, Park YB (2004) Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363:751–756PubMedCrossRef

77.

Kastrup J (2003) Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy? Curr Gene Ther 3:197–206PubMedCrossRef

78.

Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y, Tsuboi K, Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K, Fukuda K (2004) Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 104:3581–3587. doi:10.1182/blood-2004-04-1488 PubMedCrossRef

79.

Kawamoto A, Murayama T, Kusano K, Ii M, Tkebuchava T, Shintani S, Iwakura A, Johnson I, von Samson P, Hanley A, Gavin M, Curry C, Silver M, Ma H, Kearney M, Losordo DW (2004) Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation 110:1398–1405PubMedCrossRef

80.

Kirshenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo KM, Metcalfe DD (1992) Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 148:772–777PubMed

81.

Kitamura Y, Yokoyama M, Matsuda H, Ohno T, Mori KJ (1981) Spleen colony-forming cell as common precursor for tissue mast cells and granulocytes. Nature 291:159–160PubMedCrossRef

82.

Kleinbongard P, Heusch G, Schulz R (2010) TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 127:295–314. doi:10.1016/j.pharmthera.2010.05.002 PubMedCrossRef

83.

Knoops S, Groeneveld AB, Kamp O, Lagrand WK, Hoekman K (2001) Granulocyte-macrophage colony-stimulating factor (GM-CSF) decreases left ventricular function. An echocardiographic study in cancer patients. Cytokine 14:184–187. doi:10.1006/cyto.2001.0869

84.

Kronenwett R, Martin S, Haas R (2000) The role of cytokines and adhesion molecules for mobilization of peripheral blood stem cells. Stem Cells 18:320–330PubMedCrossRef

85.

Kuang D, Zhao X, Xiao G, Ni J, Feng Y, Wu R, Wang G (2008) Stem cell factor/c-kit signaling mediated cardiac stem cell migration via activation of p38 MAPK. Basic Res Cardiol 103:265–273. doi:10.1007/s00395-007-0690-z PubMedCrossRef

86.

Kuethe F, Figulla HR, Herzau M, Voth M, Fritzenwanger M, Opfermann T, Pachmann K, Krack A, Sayer HG, Gottschild D, Werner GS (2005) Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am Heart J 150:115PubMedCrossRef

87.

Kuhlmann MT, Kirchhof P, Klocke R, Hasib L, Stypmann J, Fabritz L, Stelljes M, Tian W, Zwiener M, Mueller M, Kienast J, Breithardt G, Nikol S (2006) G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. J Exp Med 203:87–97PubMedCrossRef

88.

Lehrke S, Mazhari R, Durand DJ, Zheng M, Bedja D, Zimmet JM, Schuleri KH, Chi AS, Gabrielson KL, Hare JM (2006) Aging impairs the beneficial effect of granulocyte colony-stimulating factor and stem cell factor on post-myocardial infarction remodeling. Circ Res 99:553–560. doi:10.1161/01.RES.0000238375.88582.d8 PubMedCrossRef

89.

Leone AM, Galiuto L, Garramone B, Rutella S, Giannico MB, Brugaletta S, Perfetti M, Liuzzo G, Porto I, Burzotta F, Niccoli G, Biasucci LM, Leone G, Rebuzzi AG, Crea F (2007) Usefulness of granulocyte colony-stimulating factor in patients with a large anterior wall acute myocardial infarction to prevent left ventricular remodeling (the rigenera study). Am J Cardiol 100:397–403. doi:10.1016/j.amjcard.2007.03.036 PubMedCrossRef

90.

Leone AM, Rutella S, Bonanno G, Contemi AM, de Ritis DG, Giannico MB, Rebuzzi AG, Leone G, Crea F (2006) Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol 111:202–208PubMedCrossRef

91.

Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Ogino A, Maruyama R, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H (2007) Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy. Lab Invest 87:440–455PubMedCrossRef

92.

Li Y, Fukuda N, Yokoyama S, Kusumi Y, Hagikura K, Kawano T, Takayama T, Matsumoto T, Satomi A, Honye J, Mugishima H, Mitsumata M, Saito S (2006) Effects of G-CSF on cardiac remodeling and arterial hyperplasia in rats. Eur J Pharmacol 549:98–106PubMedCrossRef

93.

Li Y, Takemura G, Okada H, Miyata S, Esaki M, Maruyama R, Kanamori H, Li L, Ogino A, Misao Y, Khai NC, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H (2006) Treatment with granulocyte colony-stimulating factor ameliorates chronic heart failure. Lab Invest 86:32–44PubMedCrossRef

94.

Liem A, van de Woestijne AP, Bruijns E, Roeters van Lennep HW, de Boo JA, van Halteren HK, van Es TP, Jukema JW, van der Laarse A, Zwinderman AH, van Veldhuisen DJ (2009) Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 131:285–287. doi:10.1016/j.ijcard.2007.07.076 PubMedCrossRef

95.

Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, van Zonneveld AJ, Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20:135–141. doi:10.1007/s10557-006-7680-5 PubMedCrossRef

96.

Louzada RA, Oliveira PF, Cavalcanti-de-Albuquerque JP, Cunha-Carvalho L, Baldanza MR, Kasai-Brunswick TH, Goldenberg RC, Campos-de-Carvalho AC, Werneck-de-Castro JP (2010) Granulocyte-colony stimulating factor treatment of chronic myocardial infarction. Cardiovasc Drugs Ther 24:121–130. doi:10.1007/s10557-010-6215-2 PubMedCrossRef

97.

Lu L, Walker D, Graham CD, Waheed A, Shadduck RK, Broxmeyer HE (1988) Enhancement of release from MHC class II antigen-positive monocytes of hematopoietic colony stimulating factors CSF-1 and G-CSF by recombinant human tumor necrosis factor-alpha: synergism with recombinant human interferon-gamma. Blood 72:34–41PubMed

98.

Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR et al (1993) Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75:1157–1167PubMedCrossRef

99.

Ma J, Ge J, Zhang S, Sun A, Shen J, Chen L, Wang K, Zou Y (2005) Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol 100:217–223. doi:10.1007/s00395-005-0521-z PubMedCrossRef

100.

Madonna R, Rokosh G, De Caterina R, Bolli R (2010) Hepatocyte growth factor/Met gene transfer in cardiac stem cells—potential for cardiac repair. Basic Res Cardiol 105:443–452. doi:10.1007/s00395-010-0102-7 PubMedCrossRef

101.

Maekawa Y, Anzai T, Yoshikawa T, Asakura Y, Takahashi T, Ishikawa S, Mitamura H, Ogawa S (2002) Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol 39:241–246PubMedCrossRef

102.

Maekawa Y, Anzai T, Yoshikawa T, Sugano Y, Mahara K, Kohno T, Takahashi T, Ogawa S (2004) Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 44:1510–1520PubMedCrossRef

103.

Maiese K, Li F, Chong ZZ (2005) New avenues of exploration for erythropoietin. JAMA 293:90–95PubMedCrossRef

104.

Malipiero UV, Frei K, Fontana A (1990) Production of hemopoietic colony-stimulating factors by astrocytes. J Immunol 144:3816–3821PubMed

105.

McLemore ML, Grewal S, Liu F, Archambault A, Poursine-Laurent J, Haug J, Link DC (2001) STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 14:193–204 (pii:S1074-7613(01)00101-7)PubMedCrossRef

106.

Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, Zetter BR (1992) The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 79:958–963PubMed

107.

Metcalf D (2008) Hematopoietic cytokines. Blood 111:485–491. doi:10.1182/blood-2007-03-079681 PubMedCrossRef

108.

Minatoguchi S, Takemura G, Chen XH, Wang N, Uno Y, Koda M, Arai M, Misao Y, Lu C, Suzuki K, Goto K, Komada A, Takahashi T, Kosai K, Fujiwara T, Fujiwara H (2004) Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 109:2572–2580PubMedCrossRef

109.

Misao Y, Takemura G, Arai M, Ohno T, Onogi H, Takahashi T, Minatoguchi S, Fujiwara T, Fujiwara H (2006) Importance of recruitment of bone marrow-derived CXCR4+ cells in post-infarct cardiac repair mediated by G-CSF. Cardiovasc Res 71:455–465PubMedCrossRef

110.

Mitsui H, Furitsu T, Dvorak AM, Irani AM, Schwartz LB, Inagaki N, Takei M, Ishizaka K, Zsebo KM, Gillis S et al (1993) Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci USA 90:735–739PubMedCrossRef

111.

Miyata S, Takemura G, Kawase Y, Li Y, Okada H, Maruyama R, Ushikoshi H, Esaki M, Kanamori H, Li L, Misao Y, Tezuka A, Toyo-Oka T, Minatoguchi S, Fujiwara T, Fujiwara H (2006) Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor. Am J Pathol 168:386–397PubMedCrossRef

112.

Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 100:11612–11617PubMedCrossRef

113.

Naito K, Anzai T, Sugano Y, Maekawa Y, Kohno T, Yoshikawa T, Matsuno K, Ogawa S (2008) Differential effects of GM-CSF and G-CSF on infiltration of dendritic cells during early left ventricular remodeling after myocardial infarction. J Immunol 181:5691–5701 (pii:181/8/5691)PubMed

114.

Neipp M, Zorina T, Domenick MA, Exner BG, Ildstad ST (1998) Effect of FLT3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: kinetics and repopulating potential. Blood 92:3177–3188PubMed

115.

Nian M, Lee P, Khaper N, Liu P (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94:1543–1553. doi:10.1161/01.RES.0000130526.20854 PubMedCrossRef

116.

Norol F, Merlet P, Isnard R, Sebillon P, Bonnet N, Cailliot C, Carrion C, Ribeiro M, Charlotte F, Pradeau P, Mayol JF, Peinnequin A, Drouet M, Safsafi K, Vernant JP, Herodin F (2003) Influence of mobilized stem cells on myocardial infarct repair in a nonhuman primate model. Blood 102:4361–4368PubMedCrossRef

117.

Ohki Y, Heissig B, Sato Y, Akiyama H, Zhu Z, Hicklin DJ, Shimada K, Ogawa H, Daida H, Hattori K, Ohsaka A (2005) Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J 19:2005–2007PubMed

118.

Ohtsuka M, Takano H, Zou Y, Toko H, Akazawa H, Qin Y, Suzuki M, Hasegawa H, Nakaya H, Komuro I (2004) Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J 18:851–853PubMed

119.

Okayama Y, Kawakami T (2006) Development, migration, and survival of mast cells. Immunol Res 34:97–115. doi:10.1385/IR:34:2:97 PubMedCrossRef

120.

Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410:701–705PubMedCrossRef

121.

Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P (2001) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 98:10344–10349PubMedCrossRef

122.

Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y, Kobayashi Y, Takeyama Y, Kobayashi N, Yoshimura N, Akazawa K, Aizawa Y (2010) Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction—randomized controlled pilot trial of EPO/AMI-1 study. Circ J 74:1415–1423 (pii:JST.JSTAGE/circj/CJ-10-0109)PubMedCrossRef

123.

Pajkrt D, Manten A, van der Poll T, Tiel-van Buul MM, Jansen J, Wouter ten Cate J, van Deventer SJ (1997) Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 90:1415–1424PubMed

124.

Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL (1995) Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86:4422–4429PubMed

125.

Parissis JT, Adamopoulos S, Venetsanou K, Kostakis G, Rigas A, Karas SM, Kremastinos D (2004) Plasma profiles of circulating granulocyte-macrophage colony-stimulating factor and soluble cellular adhesion molecules in acute myocardial infarction. Contribution to post-infarction left ventricular dysfunction. Eur Cytokine Netw 15:139–144PubMed

126.

Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas SM, Kremastinos DT (2000) Clinical and neurohormonal correlates of circulating granulocyte-macrophage colony-stimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 86:707–710, A709–A710

127.

Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112:999–1007PubMed

128.

Pimentel E (1990) Colony-stimulating factors. Ann Clin Lab Sci 20:36–55PubMed

129.

Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajjar RJ (2007) Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292:H522–H529PubMedCrossRef

130.

Quinn CM, Dawn B (2010) G-CSF and erythropoietin combination therapy for infarct repair: two plus two equals two? Editorial to: “Cytokine combination therapy with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction” by F.S. Angeli et al. Cardiovasc Drugs Ther. doi:10.1007/s10557-010-6268-2

131.

Ratajczak J, Majka M, Kijowski J, Baj M, Pan ZK, Marquez LA, Janowska-Wieczorek A, Ratajczak MZ (2001) Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. Br J Haematol 115:195–204PubMedCrossRef

132.

Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell’Era P, Nico B, Roncali L, Dammacco F (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627–2636PubMed

133.

Ripa RS, Jorgensen E, Wang Y, Thune JJ, Nilsson JC, Sondergaard L, Johnsen HE, Kober L, Grande P, Kastrup J (2006) Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 113:1983–1992PubMedCrossRef

134.

Ripa RS, Wang Y, Jorgensen E, Johnsen HE, Hesse B, Kastrup J (2006) Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 27:1785–1792PubMedCrossRef

135.

Sanganalmath SK, Stein AB, Guo Y, Tiwari S, Hunt G, Vincent RJ, Huang Y, Rezazadeh A, Ildstad ST, Dawn B, Bolli R (2009) The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up. J Mol Cell Cardiol 47:528–535. doi:10.1016/j.yjmcc.2009.07.009 PubMedCrossRef

136.

Seeger FH, Sedding D, Langheinrich AC, Haendeler J, Zeiher AM, Dimmeler S (2010) Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol 105:389–397. doi:10.1007/s00395-009-0072-9 PubMedCrossRef

137.

Seiler C, Pohl T, Wustmann K, Hutter D, Nicolet PA, Windecker S, Eberli FR, Meier B (2001) Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 104:2012–2017PubMedCrossRef

138.

Sesti C, Hale SL, Lutzko C, Kloner RA (2005) Granulocyte colony-stimulating factor and stem cell factor improve contractile reserve of the infarcted left ventricle independent of restoring muscle mass. J Am Coll Cardiol 46:1662–1669PubMedCrossRef

139.

Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T (2001) Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103:2776–2779PubMedCrossRef

140.

Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G (2009) Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104:15–18. doi:10.1161/CIRCRESAHA.108.186429 PubMedCrossRef

141.

Soldi R, Primo L, Brizzi MF, Sanavio F, Aglietta M, Polentarutti N, Pegoraro L, Mantovani A, Bussolino F (1997) Activation of JAK2 in human vascular endothelial cells by granulocyte-macrophage colony-stimulating factor. Blood 89:863–872PubMed

142.

Suarez de Lezo J, Torres A, Herrera I, Pan M, Romero M, Pavlovic D, Segura J, Ojeda S, Sanchez J, Lopez Rubio F, Medina A (2005) Effects of stem-cell mobilization with recombinant human granulocyte colony stimulating factor in patients with percutaneously revascularized acute anterior myocardial infarction. Rev Esp Cardiol 58:253–261PubMedCrossRef

143.

Sudo Y, Shimazaki C, Ashihara E, Kikuta T, Hirai H, Sumikuma T, Yamagata N, Goto H, Inaba T, Fujita N, Nakagawa M (1997) Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 89:3186–3191PubMed

144.

Sugano Y, Anzai T, Yoshikawa T, Maekawa Y, Kohno T, Mahara K, Naito K, Ogawa S (2005) Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc Res 65:446–456PubMedCrossRef

145.

Suzuki K, Nagashima K, Arai M, Uno Y, Misao Y, Takemura G, Nishigaki K, Minatoguchi S, Watanabe S, Tei C, Fujiwara H (2006) Effect of granulocyte colony-stimulating factor treatment at a low dose but for a long duration in patients with coronary heart disease. Circ J 70:430–437PubMedCrossRef

146.

Takahama H, Minamino T, Hirata A, Ogai A, Asanuma H, Fujita M, Wakeno M, Tsukamoto O, Okada K, Komamura K, Takashima S, Shinozaki Y, Mori H, Mochizuki N, Kitakaze M (2006) Granulocyte colony-stimulating factor mediates cardioprotection against ischemia/reperfusion injury via phosphatidylinositol-3-kinase/Akt pathway in canine hearts. Cardiovasc Drugs Ther 20:159–165PubMedCrossRef

147.

Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T (1999) Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434–438PubMedCrossRef

148.

Takano H, Hasegawa H, Kuwabara Y, Nakayama T, Matsuno K, Miyazaki Y, Yamamoto M, Fujimoto Y, Okada H, Okubo S, Fujita M, Shindo S, Kobayashi Y, Komiyama N, Takekoshi N, Imai K, Himi T, Ishibashi I, Komuro I (2007) Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. Int J Cardiol 122:41–47PubMedCrossRef

149.

Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M, Nakahara Y, Matsubara H (2010) Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 74:2365–2371. (pii:JST.JSTAGE/circj/CJ-10-0267)PubMedCrossRef

150.

Terrovitis J, Charitos C, Dolou P, Papalois A, Eleftheriou A, Tsolakis E, Charitos E, Mponios M, Karanastasis G, Koudoumas D, Agapitos E, Nanas JN (2004) No effect of stem cell mobilization with GM-CSF on infarct size and left ventricular function in experimental acute myocardial infarction. Basic Res Cardiol 99:241–246. doi:10.1007/s00395-004-0473-8 PubMedCrossRef

151.

Theiss HD, Brenner C, Engelmann MG, Zaruba MM, Huber B, Henschel V, Mansmann U, Wintersperger B, Reiser M, Steinbeck G, Franz WM (2010) Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)—rationale, design and first interim analysis. Int J Cardiol 145:282–284. doi:10.1016/j.ijcard.2009.09.555 PubMedCrossRef

152.

Toma C, Letts DP, Tanabe M, Gorcsan J 3rd, Counihan PJ (2007) Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion. J Mol Cell Cardiol 43:130–136PubMedCrossRef

153.

Tomita S, Ishida M, Nakatani T, Fukuhara S, Hisashi Y, Ohtsu Y, Suga M, Yutani C, Yagihara T, Yamada K, Kitamura S (2004) Bone marrow is a source of regenerated cardiomyocytes in doxorubicin-induced cardiomyopathy and granulocyte colony-stimulating factor enhances migration of bone marrow cells and attenuates cardiotoxicity of doxorubicin under electron microscopy. J Heart Lung Transplant 23:577–584PubMedCrossRef

154.

Tossidou I, Dangers M, Koch A, Brandt DT, Schiffer M, Kardinal C (2008) Tyrosine phosphatase SHP-2 is a regulator of p27(Kip1) tyrosine phosphorylation. Cell Cycle 7:3858–3868. (pii:7260)PubMedCrossRef

155.

Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N (2003) Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308:990–994. (pii:S0006291X03015031)PubMedCrossRef

156.

Tsai M, Takeishi T, Thompson H, Langley KE, Zsebo KM, Metcalfe DD, Geissler EN, Galli SJ (1991) Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci USA 88:6382–6386PubMedCrossRef

157.

Tsuzuki M (2009) Bone marrow-derived cells are not involved in reendothelialized endothelium as endothelial cells after simple endothelial denudation in mice. Basic Res Cardiol 104:601–611. doi:10.1007/s00395-009-0021-7 PubMedCrossRef

158.

Ueda K, Takano H, Hasegawa H, Niitsuma Y, Qin Y, Ohtsuka M, Komuro I (2006) Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler Thromb Vasc Biol 26:e108–e113PubMedCrossRef

159.

Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K (1992) Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80:2237–2245PubMed

160.

Valgimigli M, Rigolin GM, Cittanti C, Malagutti P, Curello S, Percoco G, Bugli AM, Della Porta M, Bragotti LZ, Ansani L, Mauro E, Lanfranchi A, Giganti M, Feggi L, Castoldi G, Ferrari R (2005) Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 26:1838–1845PubMedCrossRef

161.

van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2005) Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46:125–133PubMedCrossRef

162.

Wald M, Gutnisky A, Borda E, Sterin-Borda L (1995) Erythropoietin modified the cardiac action of ouabain in chronically anaemic–uraemic rats. Nephron 71:190–196PubMedCrossRef

163.

Wang Y, Tagil K, Ripa RS, Nilsson JC, Carstensen S, Jorgensen E, Sondergaard L, Hesse B, Johnsen HE, Kastrup J (2005) Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. Int J Cardiol 100:477–483PubMedCrossRef

164.

Ward AC, Csar XF, Hoffmann BW, Hamilton JA (1996) Cyclic AMP inhibits expression of D-type cyclins and cdk4 and induces p27Kip1 in G-CSF-treated NFS-60 cells. Biochem Biophys Res Commun 224:10–16. doi:10.1006/bbrc.1996.0976 PubMedCrossRef

165.

Weihrauch D, Arras M, Zimmermann R, Schaper J (1995) Importance of monocytes/macrophages and fibroblasts for healing of micronecroses in porcine myocardium. Mol Cell Biochem 147:13–19PubMedCrossRef

166.

Wells JA, de Vos AM (1996) Hematopoietic receptor complexes. Annu Rev Biochem 65:609–634. doi:10.1146/annurev.bi.65.070196.003141 PubMedCrossRef

167.

Werneck-de-Castro JP, Costa ESRH, de Oliveira PF, Pinho-Ribeiro V, Mello DB, Pecanha R, Mattos E, Olivares EL, Maia AC, Mill JG, Dos Santos Goldenberg RC, Campos-de-Carvalho AC (2006) G-CSF does not improve systolic function in a rat model of acute myocardial infarction. Basic Res Cardiol 101:494–501PubMedCrossRef

168.

Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2007) Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28:2018–2027PubMedCrossRef

169.

Woldbaek PR, Hoen IB, Christensen G, Tonnessen T (2002) Gene expression of colony-stimulating factors and stem cell factor after myocardial infarction in the mouse. Acta Physiol Scand 175:173–181PubMedCrossRef

170.

Woo YJ, Grand TJ, Berry MF, Atluri P, Moise MA, Hsu VM, Cohen J, Fisher O, Burdick J, Taylor M, Zentko S, Liao G, Smith M, Kolakowski S, Jayasankar V, Gardner TJ, Sweeney HL (2005) Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. J Thorac Cardiovasc Surg 130:321–329. doi:10.1016/j.jtcvs.2004.11.041 PubMedCrossRef

171.

Yan XQ, Briddell R, Hartley C, Stoney G, Samal B, McNiece I (1994) Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor. Blood 84:795–799PubMed

172.

Yeghiazarians Y, Khan M, Angeli FS, Zhang Y, Jahn S, Prasad M, Mirsky R, Shih H, Minasi P, Boyle A, Grossman W (2010) Cytokine combination therapy with long-acting erythropoietin and granulocyte colony stimulating factor improves cardiac function but is not superior than monotherapy in a mouse model of acute myocardial infarction. J Card Fail 16:669–678. doi:10.1016/j.cardfail.2010.03.008 PubMedCrossRef

173.

Zohlnhofer D, Dibra A, Koppara T, de Waha A, Ripa RS, Kastrup J, Valgimigli M, Schomig A, Kastrati A (2008) Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J Am Coll Cardiol 51:1429–1437. doi:10.1016/j.jacc.2007.11.073 PubMedCrossRef

174.

Zohlnhofer D, Ott I, Mehilli J, Schomig K, Michalk F, Ibrahim T, Meisetschlager G, von Wedel J, Bollwein H, Seyfarth M, Dirschinger J, Schmitt C, Schwaiger M, Kastrati A, Schomig A (2006) Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. Jama 295:1003–1010PubMedCrossRef

Title: Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond
Authors: Santosh K. Sanganalmath
Ahmed Abdel-Latif
Roberto Bolli
Yu-Ting Xuan
Buddhadeb Dawn
Publication date: 01-09-2011
Publisher: Springer-Verlag
Published in: Basic Research in Cardiology / Issue 5/2011
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-011-0183-y

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Opposing effects of monomeric and pentameric C-reactive protein on endothelial progenitor cells

Effect of sulfur dioxide preconditioning on rat myocardial ischemia/reperfusion injury by inducing endoplasmic reticulum stress

The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling

NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies

In vitro epithelial-to-mesenchymal transformation in human adult epicardial cells is regulated by TGFβ-signaling and WT1

Oxidative stress-induced formation of a positive-feedback loop for the sustained activation of p38 MAPK leading to the loss of cell division in cardiomyocytes soon after birth

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page